OBJECTIVE: To determine whether angiogenesis can be used as an additional prognostic indicator in patients with stage 1 germ cell tumours of the testis. PATIENTS AND METHODS: Paraffin sections were assessed immunohistochemically from 51 patients with clinical stage 1 germ cell tumours of the testis (28 seminoma, 23 teratoma) treated by orchidectomy and surveillance only. Sections were analysed for microvascular density (MVD), and expression of the angiogenic factors vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP). In addition, in the seminoma cases the presence of mRNA for the lymphangiogenic factor VEGF-C was examined by in situ hybridization, and its corresponding receptor VEGFR-3 by immunohistochemistry. RESULTS: Teratoma specimens had a significantly higher mean (range) MVD (85, 26-163; P < 0.01) than both seminoma (37, 16-91) and four normal specimens (26, 18-30). Teratoma specimens also had significantly higher VEGF expression than both seminoma and normal specimens (P < 0.01). Despite these differences between groups, and indeed individual tumours, there was no significant correlation between MVD and VEGF, or between either MVD or VEGF and relapse-free survival. TP expression was significantly greater in tumours than in normal specimens (P < 0.02) but with very little inter-tumour variation. VEGF-C mRNA and VEGFR-3 protein were detected in a third to a half of cases, with expression mostly around endothelial vessels. CONCLUSIONS: The marked differences between normal testis and tumours implicate angiogenesis in the biology of germ cell tumours of the testis. In addition, the detection of factors involved in lymphangiogenesis in some seminomas, tumours which initially metastasize primarily to lymph nodes, indicate that although not prognostic in this study, further studies are warranted in both these areas in the search for further prognostic indicators and therapeutic targets.
OBJECTIVE: To determine whether angiogenesis can be used as an additional prognostic indicator in patients with stage 1 germ cell tumours of the testis. PATIENTS AND METHODS: Paraffin sections were assessed immunohistochemically from 51 patients with clinical stage 1 germ cell tumours of the testis (28 seminoma, 23 teratoma) treated by orchidectomy and surveillance only. Sections were analysed for microvascular density (MVD), and expression of the angiogenic factors vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP). In addition, in the seminoma cases the presence of mRNA for the lymphangiogenic factor VEGF-C was examined by in situ hybridization, and its corresponding receptor VEGFR-3 by immunohistochemistry. RESULTS:Teratoma specimens had a significantly higher mean (range) MVD (85, 26-163; P < 0.01) than both seminoma (37, 16-91) and four normal specimens (26, 18-30). Teratoma specimens also had significantly higher VEGF expression than both seminoma and normal specimens (P < 0.01). Despite these differences between groups, and indeed individual tumours, there was no significant correlation between MVD and VEGF, or between either MVD or VEGF and relapse-free survival. TP expression was significantly greater in tumours than in normal specimens (P < 0.02) but with very little inter-tumour variation. VEGF-C mRNA and VEGFR-3 protein were detected in a third to a half of cases, with expression mostly around endothelial vessels. CONCLUSIONS: The marked differences between normal testis and tumours implicate angiogenesis in the biology of germ cell tumours of the testis. In addition, the detection of factors involved in lymphangiogenesis in some seminomas, tumours which initially metastasize primarily to lymph nodes, indicate that although not prognostic in this study, further studies are warranted in both these areas in the search for further prognostic indicators and therapeutic targets.
Authors: Ralph Brehm; Christina Rüttinger; Petra Fischer; Isabella Gashaw; Elke Winterhager; Sabine Kliesch; Rainer M Bohle; Klaus Steger; Martin Bergmann Journal: Neoplasia Date: 2006-06 Impact factor: 5.715
Authors: B Nitzsche; C Gloesenkamp; M Schrader; M Ocker; R Preissner; M Lein; A Zakrzewicz; B Hoffmann; M Höpfner Journal: Br J Cancer Date: 2010-06-15 Impact factor: 7.640
Authors: B Nitzsche; C Gloesenkamp; M Schrader; B Hoffmann; F Zengerling; S Balabanov; F Honecker; M Höpfner Journal: Br J Cancer Date: 2012-11-20 Impact factor: 7.640
Authors: Ana Silvia Corlan; Anca Maria Cîmpean; Adriana-Andreea Jitariu; Eugen Melnic; Marius Raica Journal: Int J Endocrinol Date: 2017-03-12 Impact factor: 3.257
Authors: Oscar Arrieta; Rosa Mayela Michel Ortega; Julián Angeles-Sánchez; Cynthia Villarreal-Garza; Alejandro Avilés-Salas; José G Chanona-Vilchis; Elena Aréchaga-Ocampo; Arturo Luévano-González; Miguel Angel Jiménez; José Luis Aguilar Journal: J Exp Clin Cancer Res Date: 2009-08-27
Authors: Mercè Juliachs; August Vidal; Xavier Garcia Del Muro; Josep M Piulats; Enric Condom; Oriol Casanovas; Mariona Graupera; Jose R Germà; Alberto Villanueva; Francesc Viñals Journal: BMC Cancer Date: 2013-08-10 Impact factor: 4.430
Authors: F Selle; J Gligorov; S Richard; A Khalil; I Alexandre; D Avenin; S Provent; D G Soares; J P Lotz Journal: Braz J Med Biol Res Date: 2014-11-04 Impact factor: 2.590